Pharmasset
 |
|
| Industry | Pharmaceuticals |
|---|---|
| Fate | Acquired by Gilead Sciences in 2012 |
| Founded | 1998 |
| Defunct | 2012 |
| Headquarters | Princeton, New Jersey, United States |
|
Key people
|
Raymond Schinazi Dennis Liotta |
Pharmasset Inc. was a pharmaceutical company based in Princeton, New Jersey in the United States. The company develops antiviral drugs for HIV (including racivir), hepatitis B (including clevudine, marketed as Levovir), and hepatitis C. In November 2011, Pharmasset was acquired by Gilead for $11.2 billion.
Pharmasset was founded in 1998 by Raymond Schinazi and Dennis Liotta, scientists at Emory University. The company was initially incorporated in Barbados (as Pharmasset, Ltd.) and separately in Georgia. However, the company was redomiciled as a Delaware corporation on June 8, 2004.
Pharmasset's initial public offering took place on April 27, 2007, when it was first listed on NASDAQ. The firm's return in the first three fiscal quarters (nine months) of 2011 was 278 percent. Among analysts, 17 rated the company's stock as "strong buy" or "buy," while two rated it a "hold." Pharmasset was the best performer in this period among all major U.S. among stocks trading for on January 1, 2011.
The company described itself as being a clinical-stage pharmaceutical company and stated that its primary focus is "the development of oral therapeutics for the treatment of hepatitis C virus." The company's secondary focus was the development of Racivir, an investigational antiretroviral drug for the treatment of HIV. The company's research and development concentrated on nucleoside analogs.
...
Wikipedia